Indication
Advanced Hematologic Malignancy
1 clinical trial
2 products
1 drug
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-09-01
Drug
FHD-286Product
Low Dose CytarabineProduct
Decitabine